**GU Cancer Clinical Trials**

**UCI 16-76** Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) (Mar)
- Cohort A is suspended.

**UCI 17-25** A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/ Prednisone) (Uchio)

**UCI 17-86** Phase 1 Trial of Efficacy and Feasibility of Robot Assisted Salvage Pelvic Lymph Node Dissection (RS-PLND) or Robot Assisted Salvage Pelvic Mass Resection (RS-PMR) Post-Robot Assisted Radical Prostatectomy (Ahlering)

**UCI 18-47** A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies (TALAPRO-2) (Uchio)

**UCI 18-13** A Randomized Phase III, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer (Uchio)

**UCI 17-41** A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (Uchio)

**Non-Metastatic**

**Metastatic**

**Both**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**Opening soon**

Version 12/18
**Opening soon**

**For more details contact**
1-877-UC-STUDY or ucstudy@uci.edu

**Version 12/18**
**GU Cancer Clinical Trials**

**UCI 15-77** A Phase II Clinical Trial to study the efficacy and safety of Pembrolizumab (MK-3475) in subjects with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy (Uchio)

**UCI 17-18** A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy (Mar)
  - Cohort 2: Platinum-naïve and cisplatin ineligible

**UCI 18-35** A Phase II, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) (Uchio)

**UCI 18-52** A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) with Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guerin (BCG)-Unresponsive Patients with or without Papillary NMIBC (RITE-USA) (Uchio)

**UCI 18-53** A Phase III, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with Intermediate or High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) (Uchio)

**UCI 18-54** An Open-Label, Randomized Phase III Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (Mar)

**UCI 18-102** A Phase III, Randomized, Study of Neoadjuvant Chemotherapy Alone versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab and BMS-986205 in Participants with Muscle Invasive Bladder Cancer (Uchio)

**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
**Opening soon**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**UCI 16-01** Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)
- 16: Cell tumor of the testes and extragonadal germ tumors
  - A. Seminoma and testicular sex cord cancer
  - B. Non seminomatous tumor
  - C. Teratoma with malignant transformation
- 17: Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis
- 18: Squamous cell carcinoma variants of the genitourinary (GU) system
- 19: Spindle cell carcinoma of kidney, pelvis, ureter

**UCI 16-96** A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Zhu)

**UCI 18-14** A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

**UCI 18-19** An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Zhu)

**UCI 18-21** A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) (Ou)

**UCI 18-101** A Phase I Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics of PF-06952229 in Adult Patients with Advanced Solid Tumors (Uchio)

---

**UCI 17-90** A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy (Ou)

**UCI 07-40** Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

**Prostate/Bladder**

**Renal**

**BASKET TRIALS**

**GU Cancer Clinical Trials**